Triptorelin vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
TriptorelinGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- Depot forms: weeks to months; aqueous: 6-8 hours
- ~5 days
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 100 mcg
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Single injection
- Once weekly, subcutaneous
- Key Benefits
- Rapid HPG axis restart after steroid use
- Single-injection PCT protocol possible
- Massively elevates LH and FSH via flare effect
- Restores endogenous testosterone faster than traditional PCT
- FDA-approved for established medical uses
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Initial testosterone flare (intended)
- Injection site reactions
- Hot flashes (with chronic use)
- Decreased libido (chronic dosing)
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —